Dengue Tetravalent Vaccine Live Brand Name– DENGVAXIA
What is Dengue Tetravalent Vaccine Live
Dengue tetravalent vaccine, live is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4 in patients 9 to 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
Dengue disease is a mosquito-borne viral infection. The first infection with dengue virus is typically mild and results in either no symptoms or a mild illness.
A subsequent infection can lead to severe dengue, including dengue hemorrhagic fever (DHF), which can be fatal. Symptoms may include abdominal pain, persistent vomiting, bleeding, confusion, and difficulty breathing.
Severe dengue is a potentially deadly complication due to plasma leaking, fluid accumulation, respiratory distress, severe bleeding, or organ impairment. Since there is no approved treatment for dengue disease, care is limited to management of symptoms.
The dengue tetravalent vaccine, live has been shown to be efficacious in pediatric patients 9 to 16 years of age who have had a previous dengue virus infection, but carries an increased risk of severe dengue in patients who experience their first natural dengue infection after vaccination.
Previous dengue infection should be confirmed through a medical record of a previous laboratory-confirmed dengue infection or through serological testing prior to vaccination.
During 3 randomized, placebo-controlled studies including 35,000 patients, the vaccine was approximately 76% effective in preventing symptomatic dengue disease in pediatric patients 9 to 16 years of age who previously had laboratory-confirmed disease.
Indications
- dengue prophylaxis
For dengue prophylaxis caused by dengue virus serotypes 1, 2, 3, and 4 in patients with laboratory-confirmed previous dengue infection and living in an endemic area
Side Effects
- abdominal pain
- anaphylactoid reactions
- asthenia
- dyspnea
- erythema
- fever
- headache
- hematoma
- infection
- injection site reaction
- malaise
- myalgia
- pruritus
- seizures
- urticaria
- vertigo
- vomiting
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- acquired immunodeficiency syndrome (AIDS)
- agammaglobulinemia
- breast-feeding
- corticosteroid therapy
- human immunodeficiency virus (HIV) infection
- hypogammaglobulinemia
- immunosuppression
- infection
- intramuscular administration
- intravenous administration
- laboratory test interference
- leukemia
- lymphoma
- neoplastic disease
- pregnancy
- radiation therapy
- severe combined immunodeficiency (SCID)
- syncope
Interactions
No information is available regarding drug interactions associated with Dengue Tetravalent Vaccine Live